Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study

We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary out...

Descripción completa

Detalles Bibliográficos
Autores principales: Alattar, Rand A., Abdalla, Shiema, Abdallah, Tasneem, Kazman, Rashid, Qadmour, Aseelah, Ibrahim, Tawheeda, Alhariri, Bassem, Shaar, Shahd H., Bajwa, Abeer, Alimam, Abeir, Qazi, Rabia, Ben Abid, Fatma, Daghfal, Joanne, Eldeeb, Ali, Shukri, Kinda, Elsayed, Ahmed, Rustom, Fatima, Alsamawi, Musaed, Abdelmajid, Alaaeldin, Basulto, Miguel A.P., Cobian, Armando A.R., Abukhattab, Mohamed, Alkhal, Abdullatif, Almaslamani, Muna A., Omrani, Ali S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420008/
https://www.ncbi.nlm.nih.gov/pubmed/36087547
http://dx.doi.org/10.1016/j.jiph.2022.08.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420008/
https://www.ncbi.nlm.nih.gov/pubmed/36087547
http://dx.doi.org/10.1016/j.jiph.2022.08.011

Ejemplares similares